Abstract: Cardiac remodeling is an important pathophysiological basis for the occurrence and development of cardiovascular disease and is closely related to the prognosis of patients. LCZ696 is an angiotensin receptor neprilysin inhibitor, which acts on both renin-angiotensin-aldosterone system (RAAS) and natriuretic peptide system. It is mainly used in the treatment of heart failure with decreased ejection fraction. Recent studies have shown that compared with renin-angiotensin system inhibitor (RASI), LCZ696 can significantly inhibit cardiac remodeling and improve cardiac function and prognosis in different types of cardiovascular diseases. This article reviews the mechanism and research status of the inhibitory effect of LCZ696 on cardiac remodeling.

Key words: heart failure, myocardial infraction, cardiomyopathies, cardiac remodeling, sacubitril and valsartan